At Investor Confab, Illumina Details 'Enormous' DTC Demand as Market Shifts to Less Complex Chips | GenomeWeb

The market for microarrays continues to grow, thanks to demand from direct-to-consumer genetics companies, as well as researchers who now favor using lower-complexity arrays in larger studies, according to Illumina CEO Jay Flatley.

Because of this demand for lower-complexity chips, Illumina has set aside earlier plans to debut higher-density whole-genome genotyping arrays containing up to 20 million variants, Flatley said during a presentation at Bank of America Merrill Lynch's Global Healthcare Conference, held last week in Las Vegas.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: a global genetic interaction map for Saccharomyces cerevisiae, and progress made in genomics, precision medicine, and therapeutics.

The price of plane tickets can affect how scientists in different countries choose to collaborate with each other, NPR reports.

The Annals of Improbable Research has awarded the 2016 Ig Nobel Prizes.

Scientific American alleges that the FDA has been "arm-twisting journalists into relinquishing their reportorial independence."